Scientists from the University of California have announced a possible alternative option to electronic eye implants for those who have lost their sight: gene therapy. Virus-delivered genes for green opsin gave blind mice sight enough to determine patterns on an iPad, they found, with the therapy possibly ready for clinical trials in three years’ time.
The scientists of seven nations have called for a halt to gene-editing experiments seeking to alter heritable traits in human babies.
Oxford Nanopore has made its Flongle starter packs available to purchase, following an early-access testing programme. The Flongle machine allows for smaller, on-demand DNA sequence testing at low cost.
Commercial DNA-analysing company 23andMe is looking to launch a new DNA assessment to help individuals discover their risk of developing type 2 diabetes. Several million customers will receive the information over the coming weeks.
Researchers at Cold Spring Harbor Laboratory have created a list of genetic “usual suspects” from a computational analysis of 635 datasets across around 27,000 genetic samples.
The eLife online journal has published its first “computationally reproducible” article, where figures are integrated with the software, data and computational environment required to produce them.
A neuron-optimised CRISPR-Cas9 activation system has been used by scientists to regulate genes in a rat brain for the first time. This technique could lead to researchers being able to probe genetic influences on brain health and disease in model organisms which more closely resemble humans.
New information from China has suggested that the twins recently created using CRISPR gene-editing technology to make them HIV-resistance could also develop genetically-enhanced brains.
Researchers from the Wake Forest Institute for Regenerative Medicine (WFIRM) have determined a new way to deliver DNA editing tools so that the presence of their proteins in cells is reduced, in what they have called a “hit and run” approach.
Global life science researcher Bio-Rad has announced that its droplet digital PCR-based test for chronic myeloid leukaemia (CML), the first of its kind, has been cleared by the FDA. The test quantifies BCR-ABL, the gene fusion which causes CML, in the blood.
TEXLab, a mathematical AI software created by scientists at Imperial College London and the University of Melbourne can predict survival rates of patients with ovarian cancer more accurately than any current method, a trial published in Nature Communications has found.
The leading advisor for the UK science and technology (S&T) sectors has estimated that despite Brexit, Cambridge and Oxford’s S&T companies will require 2.5 million more square feet of lab and research space over the next five years, and are looking to accommodate 20,000 new R&D workers by 2023.
Esketamine, a Johnson & Johnson antidepressant based on the party drug ketamine, has received backing from an FDA independent advisory group.
Toxic antibody tisutumab vedotin (TV) has shown promise as a treatment for a number of types of advanced cancer. This “trojan horse” approach has now reached the stage of being tested on a wider variety of patients. Institute of Cancer Research and Royal Marsden NHS Foundation Trust researchers tested the drug on 147 patients to evaluate potential benefits and side effects.